Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Fig. 4

ADA and NAb incidence by study visit (safety population). a ADA incidence. b NAb incidence. The percentage of NAb-positive patients is based on the total number of patients in each treatment group. a“Overall” includes data from week 2, week 6, week 12, week 26, end-of-treatment/early termination, follow-up, and unplanned visits in treatment period 1. Abbreviations: ADA anti-drug antibody, Adalimumab-EU adalimumab sourced from the European Union, NAb neutralizing antibody

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us